The Role of Local Ablative Therapy in Oligometastatic Non-Small-Cell Lung Cancer: Hype or Hope

References

• American Cancer Society . Cancer Facts & Figures 2016.American Cancer Society, Atlanta, GA, USA (2016).
   Google Scholar
• Molina JR , YangP, CassiviSD, SchildSE, AdjeiAA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proc.83(5), 584–594 (2008).
   PubMed Web of Science ®Google Scholar
• Fossella F , PereiraJR, Von PawelJet al. Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol.21(16), 3016–3024 (2003).
   PubMed Web of Science ®Google Scholar
• Chan BA , HughesBGM. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl. Lung Cancer Res.4(1), 36–54 (2015).
   PubMed Web of Science ®Google Scholar
• Timmerman RD , KavanaghBD. Stereotactic body radiation therapy. Curr. Probl. Cancer29(3), 120–157 (2005).
   PubMed Web of Science ®Google Scholar
• Potters L , KavanaghB, GalvinJMet al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int. J. Radiat. Oncol. Biol. Phys.76(2), 326–332 (2010).
   PubMed Web of Science ®Google Scholar
• Halsted WS . I. The results of radical operations for the cure of carcinoma of the breast. Ann. Surg.46(1), 1–19 (1907).
   PubMedGoogle Scholar
• Fisher B . Laboratory and clinical research in breast cancer – a personal adventure: the David A. Karnofsky Memorial Lecture. Cancer Res.40(11), 3863–3874 (1980).
   PubMed Web of Science ®Google Scholar
• Hellman S , WeichselbaumRR. Oligometastases. J. Clin. Oncol.13(1), 8–10 (1995).
   PubMed Web of Science ®Google Scholar
• Hellman S . Karnofsky Memorial Lecture. Natural history of small breast cancers. J. Clin. Oncol.12(10), 2229–2234 (1994).
   PubMed Web of Science ®Google Scholar
• Torok JA , WuY, ProsnitzLRet al. Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma. Int. J. Radiat. Oncol. Biol. Phys.92(1), 54–59 (2015).
   PubMed Web of Science ®Google Scholar
• Miller TP , DahlbergS, CassadyJRet al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N. Engl. J. Med339(1), 21–26 (1998).
   PubMed Web of Science ®Google Scholar
• Rusthoven KE , HammermanSF, KavanaghBD, BirtwhistleMJ, StaresM, CamidgeDR. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol. (Stockholm, Sweden)48(4), 578–583 (2009).
   PubMed Web of Science ®Google Scholar
• Palma DA , HaasbeekCJ, RodriguesGBet al. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized Phase II trial. BMC Cancer12, 305 (2012).
   PubMed Web of Science ®Google Scholar
• Milano MT , KatzAW, ZhangH, OkunieffP. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int. J. Radiat. Oncol. Biol. Phys.83(3), 878–886 (2012).
   PubMed Web of Science ®Google Scholar
• Kavanagh BD , McGarryRC, TimmermanRD. Extracranial radiosurgery (stereotactic body radiation therapy) for oligometastases. Semin. Radiat. Oncol.16(2), 77–84 (2006).
   PubMed Web of Science ®Google Scholar
• Tait CR , WaterworthA, LoncasterJ, HorganK, DodwellD. The oligometastatic state in breast cancer: hypothesis or reality. Breast (Edinburgh, Scotland)14(2), 87–93 (2005).
   PubMed Web of Science ®Google Scholar
• Parikh RB , CroninAM, KozonoDEet al. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys.89(4), 880–887 (2014).
   PubMed Web of Science ®Google Scholar
• Yano T , OkamotoT, HaroAet al. Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer. Lung Cancer82(3), 431–435 (2013).
   PubMed Web of Science ®Google Scholar
• Nordlinger B , GuiguetM, VaillantJCet al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer77(7), 1254–1262 (1996).
   PubMed Web of Science ®Google Scholar
• Fong Y , FortnerJ, SunRL, BrennanMF, BlumgartLH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann. Surg.230(3), 309–318; discussion 318–321 (1999).
   PubMed Web of Science ®Google Scholar
• Wei AC , GreigPD, GrantD, TaylorB, LangerB, GallingerS. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann. Surg. Oncol.13(5), 668–676 (2006).
   PubMed Web of Science ®Google Scholar
• Pawlik TM , ScogginsCR, ZorziDet al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann. Surg.241(5), 715–722, discussion 714–722 (2005).
   PubMed Web of Science ®Google Scholar
• Timmerman RD , HuC, MichalskiJet al. Long-term Results of RTOG 0236: a Phase II trial of stereotactic body radiation therapy (SBRT) in the treatment of patients with medically inoperable stage I non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys.90(1), S30 (2014).
   Web of Science ®Google Scholar
• Singh D , ChenY, HareMZet al. Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. J. Thorac. Dis.6(4), 369–374 (2014).
   PubMed Web of Science ®Google Scholar
• Verstegen NE , OosterhuisJW, PalmaDAet al. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Ann. Oncol.24(6), 1543–1548 (2013).
   PubMed Web of Science ®Google Scholar
• Robinson CG , DeweesTA, El NaqaIMet al. Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer. J. Thorac. Oncol.8(2), 192–201 (2013).
   PubMed Web of Science ®Google Scholar
• Chang JY , SenanS, PaulMAet al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol.16(6), 630–637 (2015).
   PubMed Web of Science ®Google Scholar
• Patchell RA , TibbsPA, WalshJWet al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med.322(8), 494–500 (1990).
   PubMed Web of Science ®Google Scholar
• Hussain A , BrownPD, StaffordSL, PollockBE. Stereotactic radiosurgery for brainstem metastases: survival, tumor control, and patient outcomes. Int. J. Radiat. Oncol. Biol. Phys.67(2), 521–524 (2007).
   PubMed Web of Science ®Google Scholar
• Andrews DW , ScottCB, SperdutoPWet al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet363(9422), 1665–1672 (2004).
   PubMed Web of Science ®Google Scholar
• Aoyama H , ShiratoH, TagoMet al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA295(21), 2483–2491 (2006).
   PubMed Web of Science ®Google Scholar
• Chang EL , WefelJS, HessKRet al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol.10(11), 1037–1044 (2009).
   PubMed Web of Science ®Google Scholar
• O’Neill BP , IturriaNJ, LinkMJ, PollockBE, BallmanKV, O’FallonJR. A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int. J. Radiat. Oncol. Biol. Phys.55(5), 1169–1176 (2003).
   PubMed Web of Science ®Google Scholar
• Bindal AK , BindalRK, HessKRet al. Surgery versus radiosurgery in the treatment of brain metastasis. J. Neurosurg.84(5), 748–754 (1996).
   PubMed Web of Science ®Google Scholar
• Ettinger DS , WoodDE, AkerleyWet al. NCCN guidelines insights: non-small cell lung cancer, version 4.2016. J. Natl Compr. Canc. Netw.14(3), 255–264 (2016).
   PubMed Web of Science ®Google Scholar
• Porte H , SiatJ, GuibertBet al. Resection of adrenal metastases from non-small cell lung cancer: a multicenter study. Ann. Thorac. Surg.71(3), 981–985 (2001).
   PubMed Web of Science ®Google Scholar
• Scorsetti M , AlongiF, FilippiARet al. Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients. Acta Oncol. (Stockholm, Sweden)51(5), 618–623 (2012).
   PubMed Web of Science ®Google Scholar
• Holy R , PirothM, PinkawaM, EbleMJ. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther. Onkolt.187(4), 245–251 (2011).
   PubMed Web of Science ®Google Scholar
• Tanvetyanon T , RobinsonLA, SchellMJet al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J. Clin. Oncol.26(7), 1142–1147 (2008).
   PubMed Web of Science ®Google Scholar
• Luketich JD , MartiniN, GinsbergRJ, RigbergD, BurtME. Successful treatment of solitary extracranial metastases from non-small cell lung cancer. Ann. Thorac. Surg.60(6), 1609–1611 (1995).
   PubMed Web of Science ®Google Scholar
• Khan AJ , MehtaPS, ZusagTWet al. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother. Oncol.81(2), 163–167 (2006).
   PubMed Web of Science ®Google Scholar
• Hasselle MD , HarafDJ, RusthovenKEet al. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J. Thorac. Oncol.7(2), 376–381 (2012).
   PubMed Web of Science ®Google Scholar
• Lopez Guerra JL , GomezD, ZhuangYet al. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int. J. Radiat. Oncol. Biol. Phys.84(1), e61–e67 (2012).
   PubMed Web of Science ®Google Scholar
• Sheu T , HeymachJV, SwisherSGet al. Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy. Int. J. Radiat. Oncol. Biol. Phys.90(4), 850–857 (2014).
   PubMed Web of Science ®Google Scholar
• Ashworth AB , SenanS, PalmaDAet al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin. Lung. Canc.15(5), 346–355 (2014).
   PubMed Web of Science ®Google Scholar
• Weickhardt AJ , ScheierB, BurkeJMet al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J. Thorac. Oncol.7(12), 1807–1814 (2012).
   PubMed Web of Science ®Google Scholar
• Gan GN , WeickhardtAJ, ScheierBet al. stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int. J. Radiat. Oncol. Biol. Phys.88(4), 892–898 (2014).
   PubMed Web of Science ®Google Scholar
• Yu HA , SimaCS, HuangJet al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J. Thorac. Oncol.8(3), 346–351 (2013).
   PubMed Web of Science ®Google Scholar
• De Ruysscher D , WandersR, Van BaardwijkAet al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective Phase II trial (NCT01282450). J. Thorac. Oncol.7(10), 1547–1555 (2012).
   PubMed Web of Science ®Google Scholar
• Iyengar P , KavanaghBD, WardakZet al. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J. Clin. Oncol.32(34), 3824–3830 (2014).
   PubMed Web of Science ®Google Scholar
• Guerra JLL , GomezD, ZhuangYet al. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int. J. Radiat. Oncol. Biol. Phys.84(1), e61–e67 (2012).
   PubMed Web of Science ®Google Scholar
• Ciardiello F , De VitaF, OrdituraM, TortoraG. The role of EGFR inhibitors in nonsmall cell lung cancer. Curr. Opin. Oncol.16(2), 130–135 (2004).
   PubMed Web of Science ®Google Scholar
• Shigematsu H , LinL, TakahashiTet al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst.97(5), 339–346 (2005).
   PubMed Web of Science ®Google Scholar
• Skov BG , HogdallE, ClementsenPet al. The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population. APMIS123(2), 108–115 (2015).
   PubMed Web of Science ®Google Scholar
• Rosell R , MoranT, QueraltCet al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med.361(10), 958–967 (2009).
   PubMed Web of Science ®Google Scholar
• Inukai M , ToyookaS, ItoSet al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res.66(16), 7854–7858 (2006).
   PubMed Web of Science ®Google Scholar
• Sequist LV , WaltmanBA, Dias-SantagataDet al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med.3(75), 75ra26 (2011).
   PubMed Web of Science ®Google Scholar
• Browning ET , WeickhardtAJ, CamidgeDR. Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer. J. Thorac. Oncol.8(3), e21 (2013).
   PubMed Web of Science ®Google Scholar
• Folkert MR , TimmermanR. Review of treatment options for oligometastatic non-small cell lung cancer. Clin. Adv. Hematol. Oncol.13(3), 186–193 (2015).
   PubMedGoogle Scholar
• Coleman RE . Skeletal complications of malignancy. Cancer80(8 Suppl.), 1588–1594 (1997).
   PubMed Web of Science ®Google Scholar
• Tammemagi CM , Neslund-DudasC, SimoffM, KvaleP. Impact of comorbidity on lung cancer survival. Int. J. Cancer.103(6), 792–802 (2003).
   PubMed Web of Science ®Google Scholar
• Koivunen JP , MermelC, ZejnullahuKet al. EML4–ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res.14(13), 4275–4283 (2008).
   PubMed Web of Science ®Google Scholar
• Shaw AT , YeapBY, Mino-KenudsonMet al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol.27(26), 4247–4253 (2009).
   PubMed Web of Science ®Google Scholar
• Solomon BJ , MokT, KimDWet al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med.371(23), 2167–2177 (2014).
   PubMed Web of Science ®Google Scholar
• Doebele RC , PillingAB, AisnerDLet al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res.18(5), 1472–1482 (2012).
   PubMed Web of Science ®Google Scholar
• Costa DB , KobayashiS, PandyaSSet al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J. Clin. Oncol.29(15), e443–e445 (2011).
   PubMed Web of Science ®Google Scholar
• Gadgeel SM , GandhiL, RielyGJet al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a Phase 1/2 study. Lancet Oncol.15(10), 1119–1128 (2014).
   PubMed Web of Science ®Google Scholar
• Shaw AT , GandhiL, GadgeelSet al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, Phase 2 trial. Lancet Oncol.17(2), 234–242 (2016).
   PubMed Web of Science ®Google Scholar
• Kim DW , MehraR, TanDSet al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, Phase 1 trial. Lancet Oncol. doi: 10.1016/s1470–2045(15)00614-00612 (2016) ( Epub ahead of print).
   Google Scholar
• Borghaei H , Paz-AresL, HornLet al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med.373(17), 1627–1639 (2015).
   PubMed Web of Science ®Google Scholar
• Joyce JA , FearonDT. T cell exclusion, immune privilege, and the tumor microenvironment. Science (New York, NY)348(6230), 74–80 (2015).
   Google Scholar
• Lanitis E , IrvingM, CoukosG. Targeting the tumor vasculature to enhance T cell activity. Curr. Opin. Immunol.33, 55–63 (2015).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI , BronteV, ChenSHet al. The terminology issue for myeloid-derived suppressor cells. Cancer Res.67(1), 425; author reply 426 (2007).
   PubMed Web of Science ®Google Scholar
• Bluestone JA , AbbasAK. Natural versus adaptive regulatory T cells. Nature Rev. Immunology3(3), 253–257 (2003).
   PubMed Web of Science ®Google Scholar
• Valzasina B , PiconeseS, GuiducciC, ColomboMP. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res.66(8), 4488–4495 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang B , BowermanNA, SalamaJKet al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med.204(1), 49–55 (2007).
   PubMed Web of Science ®Google Scholar
• Matsumura S , WangB, KawashimaNet al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J. Immunol.181(5), 3099–3107 (2008).
   PubMed Web of Science ®Google Scholar
• Lugade AA , SorensenEW, GerberSA, MoranJP, FrelingerJG, LordEM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J. Immunol.180(5), 3132–3139 (2008).
   PubMed Web of Science ®Google Scholar
• Klug F , PrakashH, HuberPEet al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell24(5), 589–602 (2013).
   PubMed Web of Science ®Google Scholar
• Tsai CS , ChenFH, WangCCet al. Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. Int. J. Radiat. Oncol. Biol. Phys.68(2), 499–507 (2007).
   PubMed Web of Science ®Google Scholar
• Reits EA , HodgeJW, HerbertsCAet al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med.203(5), 1259–1271 (2006).
   PubMed Web of Science ®Google Scholar
• Chakraborty M , AbramsSI, CamphausenKet al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J. Immunol.170(12), 6338–6347 (2003).
   PubMed Web of Science ®Google Scholar
• Xu J , EscamillaJ, MokSet al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res.73(9), 2782–2794 (2013).
   PubMed Web of Science ®Google Scholar
• Vanpouille-Box C , DiamondJM, PilonesKAet al. TGFbeta is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res.75(11), 2232–2242 (2015).
   PubMed Web of Science ®Google Scholar
• Dewan MZ , GallowayAE, KawashimaNet al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res.15(17), 5379–5388 (2009).
   PubMed Web of Science ®Google Scholar
• Kingsley DP . An interesting case of possible abscopal effect in malignant melanoma. Br. J. Radiol.48(574), 863–866 (1975).
   PubMed Web of Science ®Google Scholar
• Robin HI , AubuchonJ, VaranasiVR, WeinsteinAB. The abscopal effect: demonstration in lymphomatous involvement of kidneys. Med. Pediatr. Oncol.9(5), 473–476 (1981).
   PubMedGoogle Scholar
• Golden EB , DemariaS, SchiffPB, ChachouaA, FormentiSC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol. Res.1(6), 365–372 (2013).
   PubMed Web of Science ®Google Scholar
• Garon EB . The race for combined checkpoint inhibition in NSCLC. Lancet Oncol.17(3), 259–260 (2016).
   PubMed Web of Science ®Google Scholar
• Wolchok JD , KlugerH, CallahanMKet al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med.369(2), 122–133 (2013).
   PubMed Web of Science ®Google Scholar
• Curti BD , Kovacsovics-BankowskiM, MorrisNet al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res.73(24), 7189–7198 (2013).
   PubMed Web of Science ®Google Scholar
• Monjazeb AM , KentMS, GrossenbacherSKet al. Blocking indolamine-2, 3-dioxygenase rebound immune suppression boosts anti-tumor effects of radio-immunotherapy in murine models and spontaneous canine malignancies. Clin. Cancer Res. doi: 10.1158/1078-0432.ccr-15-3026 (2016) ( Epub ahead of print).
   Google Scholar
• Sheridan C . IDO inhibitors move center stage in immuno-oncology. Nat. Biotech.33(4), 321–322 (2015).
   PubMed Web of Science ®Google Scholar
• Alongi F , ArcangeliS, FilippiARet al. Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist17(8), 1100–1107 (2012).
   PubMed Web of Science ®Google Scholar
• Sher DJ , WeeJO, PungliaRS. Cost–effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys.81(5), e767–e774 (2011).
   PubMed Web of Science ®Google Scholar
• Lester-Coll NH , RutterCE, BledsoeTJet al. Cost–effectiveness of surgery, stereotactic body radiation therapy, and systemic therapy for pulmonary oligometastases. Int. J. Radiat. Oncol. Biol. Phys.95(2), 663–672 (2016).
   PubMed Web of Science ®Google Scholar